78 results about "Tartrate" patented technology

A novel salt form of Compound (I) represented by the following structural formula, and its corresponding pharmaceutical compositions, are disclosed.Particular single crystalline forms of 1:1 Compound (I) tartrate salt are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating cancer in a subject.

The invention relates to an anti-aging capsule compounded by PQQ and mitochondrial nutrients, and discloses an anti-aging capsule which is prepared by synergistically compounding a plurality of mitochondrial nutrients according to a scientific proportion and supplementing high-purity raw materials and slow-release dosage forms to realize energy metabolism activation and anti-oxidation synergistic intervention. Therefore, the anti-aging capsule systematically delays aging through multi-target regulation and control of mitochondrial functions. The capsule is characterized by comprising the following components in parts by weight: 1-20 mg of pyrroloquinoline quinone disodium salt (PQQ), 20-100 mg of coenzyme Q10, 50-200 mg of L-carnitine tartrate, 10-100 mg of alpha-lipoic acid, 50-300 mg of nicotinamide mononucleotide (NMN) or nicotinamide nucleoside (NR), and 10-50 [mu] g of selenoprotein or organic selenium yeast, and a capsule carrier comprises 100 mg of gelatin or a plant-derived capsule shell, 180 mg of microcrystalline cellulose, 5 mg of magnesium stearate and 5 mg of silicon dioxide.

Sterile filtered liquid lactase composition comprising a lactase, preferably a neutral or acidic lactase, an anion selected from malate, tartrate, citrate, gluconate and / or EDTA and a cation selected from sodium and potassium. Preferably, the composition further comprises a polyol. Addition of the said anions to lactase improves filterability by reducing pressure in a filtration system. Preferably the filtration forms part of an in-line filtration system in the production of a dairy product.

This invention relates to a method for preparing the fenelone intermediate 2-cyanoethyl(4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthidine-3-carboxylic acid ester, and also relates to diastereomeric salts (Va), (Vb), (Vc), and / or (Vd). This method is simple to operate, and the diastereomeric salts can be obtained with very high chemical and enantiomeric purity (tartrate ester content <0.05%) through a single dissociation, avoiding the raw material loss and waste problems caused by multiple dissociations. It also has low production costs and meets the requirements of green production.

This invention discloses a method for resolving isomers of methylfenacin ester, comprising: firstly, dissolving methylfenacin ester in a first solvent and adding L-tartaric acid, dissolving until clear; then adjusting the system temperature to 40℃-53℃ and adding L-tartaric acid seed crystals of the target isomer; subsequently, cooling the system to 20℃-30℃, filtering the precipitated product, and obtaining the L-tartaric acid seed crystals of the target isomer as the filter cake; dissociating the L-tartaric acid seed crystals of the target isomer using an alkaline resin, collecting the filtrate, and drying the filtrate to obtain the target isomer of methylfenacin ester. This invention achieves the resolution of isomers of methylfenacin ester by using L-tartaric acid, and through optimization of conditions, achieves a yield of not less than 74.1% and an ee of 91.1% for the target isomer of methylfenacin ester. The resolution method provided by this invention is simple to operate, easy to control, suitable for large-scale production, and meets industrial needs.

Pharmaceutical compositions comprising tartrate salts of medopredane and methods for making the pharmaceutical compositions are provided. The pharmaceutical composition is useful in the treatment of diseases such as L-DOPA induced dyskinesia.

The utility model discloses a cold stable filtering equipment for brewing, include: filter jar, the top end of filter jar is used for the hole of external connection pipe, the bottom of hole is fixedly connected with the telescopic pipe for sealing shell, one side of filter jar is provided with the discharge pipe, and one end of discharge pipe extends to the inside of telescopic pipe for sealing shell through the hole, and one end of discharge pipe located telescopic pipe for sealing shell is fixedly connected with the stretch extension pipe. The utility model discloses through drawing out height control mechanism, utilize control electric push rod to push the chain wheel upward, and the chain wheel moves upward and rolls simultaneously, and make its chain located one end of telescopic pipe for sealing shell upward and pull telescopic pipe for sealing shell and stretch extension pipe synchronous rising simultaneously, promote telescopic pipe for sealing shell and stretch extension pipe rising and folding simultaneously, be favorable to according to the wine body flow rate adjustment draw out height, guarantee after the wine liquid of filtering for many times can have enough time to carry out the reprecipitation time again, guarantee the wine body tartrate can remove completely.

The application discloses an anti-caking salt product and a preparation method thereof. The anti-caking salt product comprises raw salt and an anti-caking agent, the anti-caking agent is food-grade ferric tartrate, and the addition amount of the anti-caking agent is 0.05-0.106 g / kg of the salt. The core of the anti-caking method of the salt lies in that the food-grade ferric tartrate is used as the main anti-caking agent, the addition amount is 0.05-0.106 g / kg of the salt, the salt is dried at 100 DEG C for 4 hours, then the anti-caking agent is added, and the water vapor transmission rate is less than or equal to 0.5 g / m 2 24h of high-barrier material packaging, while 6 g of quicklime or 2 g of calcium chloride desiccant is added in every 200 g of the salt. The application also controls the Mg 2+ content in the salt to be less than or equal to 0.02%, the KCl content to be less than or equal to 10%, and the particle size to be in the range of 0.45-0.6 mm, so that the salt caking is synergistically inhibited from multiple dimensions. The method has extremely significant anti-caking effect (the caking rate is only 8.7% after 15 days of open storage), is safe and economical, and has a simple process, and can effectively replace or reduce the use of potassium ferrocyanide, and is suitable for large-scale industrial production.

This invention relates to an extraction method for improving the bioavailability of tartrate tylosin. The method includes subjecting tartrate fermentation broth to a single acid-dissolution and alkali-precipitation treatment, followed by static crystallization to obtain crude tartrate. This crude tartrate is then subjected to extraction and back-extraction steps, followed by decolorization and ultrafiltration to obtain refined tartrate. Finally, it is spray-dried to obtain tartrate tylosin. This invention optimizes the extraction process of tartrate tylosin by combining a single acid-dissolution and alkali-precipitation crystallization purification process with extraction and back-extraction processes, effectively improving the bioavailability of tartrate tylosin.

This invention relates to a method for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthidine-3-carboxylic acid, and also to diastereomeric salts (Va), (Vb), (Vc), and / or (Vd). This method is simple to operate, and the diastereomeric salts can be obtained with very high chemical and enantiomeric purity (tartrate ester content <0.05%) through a single dissociation, avoiding the raw material loss and waste problems caused by multiple dissociations. It also has low production costs and meets the requirements of green production.

The application provides modified calcium carbonate, a preparation method thereof and a plugging agent containing the same. The modified calcium carbonate is a dicalcium bis-palmitoyl tartrate hydrophobic modified calcium carbonate. The plugging agent comprises the modified calcium carbonate, natural asphalt, high filtration material, degradable fiber and oil.

The application discloses a kind of compound oral muscarine antipsychotic drug compositions and preparation method thereof, belong to pharmaceutical composition technical field, its technical scheme main point is a kind of compound oral muscarine antipsychotic drug compositions, the pharmaceutical composition is the composition containing two active ingredients, the composition containing two active ingredients is the combination of xanthomelin tartrate microtablet and trospium chloride microtablet, after two active ingredients are made into microtablet respectively, while guaranteeing that product can be released faster, can also increase the time of drug retention in stomach, significantly increase the penetration absorption of drug in body, reduce the fluctuation of blood drug concentration caused by the inconsistent drug release absorption behavior after each administration, so as to better play a role in body, in addition, the technical scheme in the application does not use complex production process, reduces the process development threshold, significantly increases the process reproducibility and stability.

This invention relates to a method for preparing the fenelone intermediate 2-cyanoethyl (4S)-4-(4-cyano-2-methoxyphenyl)-5-hydroxy-2,8-dimethyl-1,4-dihydro-1,6-naphthidine-3-carboxylic acid ester, and also relates to diastereomeric salts (Va), (Vb), (Vc), and / or (Vd). This method is simple to operate, and the diastereomeric salts can be obtained with very high chemical and enantiomeric purity (tartrate ester content <0.05%) through a single dissociation, avoiding the raw material loss and waste problems caused by multiple dissociations. It also has low production costs and meets the requirements of green production.

To provide a crystal of 2 - (4-acetylbenzyl) - 3 - ((4-fluorophenyl) amino) - 577 - trimethyl-7, 8-dihydro-pyrazolo-imidazo [1, 2-a] 2H [4, 3-e] pyrimidin-4 (5H) - one.SOLUTION: Provided is a crystal of an acid addition salt form selected from, for example, succinate form, citrate form, adipate form, tartrate form (e.g., L-tartrate form), malate form, gluconate form (e.g., D-gluconate form), maleate form, fumarate form, aspartate form (e.g., L-aspartate form), hippurate form, sebacate form, glycolate form, galactarate form, benzoate form, pamoate form, oxalate form and malonate form.SELECTED DRAWING: None

The invention discloses a preparation method of cilnipride tartrate, which is characterized in that YT2303S-01 is used as a starting material, an intermediate 1 and an intermediate 2 are prepared in sequence, and finally the preparation of the cilnipride tartrate is completed. The raw materials adopted by the invention are commercially available products, the raw material sources are stable, and large-scale and industrial production can be conveniently carried out.

The invention relates to the technical field of baby food, and particularly discloses compound amino acid multi-vitamin multi-mineral soybean protein food and a preparation method thereof. The compound amino acid multi-vitamin multi-mineral soybean protein food is prepared from the following components in parts by weight: a compound amino acid mixture, soybean peptide powder, solid corn syrup, a vitamin mixture, a mineral mixture, docosahexaenoic acid powder and choline bitartrate, the preparation method comprises the following steps: S1, pretreating the raw materials; s2, pre-dispersing mineral substances; s3, vitamin premixing; s4, main mixing; s5, carrying out homogenization treatment; and S6, sieving and packaging: sieving the homogeneous mixture with a 40-mesh sieve, and then sterilizing and packaging in vacuum. The compound amino acid multi-vitamin multi-mineral soybean protein food is used for supplementing special dietary nutrition for infants and children, and has the advantages of being comprehensive in nutrition, high in absorption efficiency and capable of effectively improving the nutritional status of the infants and children and promoting growth and development.

The invention relates to the technical field of fine chemical engineering, in particular to a method for green production of D-tartaric acid by a double-compartment bipolar membrane process, which comprises the following steps: preparing a raw material sodium tartrate solution generated by hydrolysis of a sodium epoxysuccinate solution through a strain into a raw material solution with the mass concentration of 7-8.5%, and carrying out electrodialysis on the raw material solution through a double-compartment bipolar membrane electrodialysis device to obtain D-tartaric acid. Directional ion migration is realized under the action of direct current; sodium ions enter an alkali side through a positive membrane and are combined with hydroxyl ions generated by dissociation of a bipolar membrane to generate a sodium hydroxide solution with the mass concentration of 3-4%; hydrogen ions enter an acid side through the bipolar membrane and are combined with tartrate ions to generate a D-tartaric acid solution, and a D-tartaric acid finished product is obtained through subsequent concentration and drying; through the mode, one-step conversion from sodium tartrate to D-tartaric acid is realized, the cost is reduced, and the yield is improved.

This invention discloses a method for the membrane electrolytic refining of crude antimony based on a tartaric acid system, relating to the field of metal purification technology. The method includes: preparing an antimony tartrate solution, controlling the antimony ion concentration to 30–55 g / L and the tartrate ion concentration to 230–270 g / L, so that the antimony ions exist as negatively charged complex ions. After settling and filtration, crude antimony is used as the anode and a stainless steel plate as the cathode, at a current density of 200–250 A / m. 2 Pre-electrolysis is performed at 25–55°C to achieve deep purification of the solution; then, anion exchange membranes are used to separate the anode and cathode chambers, allowing only negatively charged ions to pass through; finally, the clean solution obtained from pre-electrolysis is used as the initial electrolyte, and the solution is purified at a current density of 50–200 A / m³. 2 Electrolytic refining at 25~55℃. This invention enables electrolytic refining over a wide current density range (50~250 A / m). 2 It operates stably for a long time within a temperature range (15~55 ℃), and obtains high-quality refined antimony products with dense crystals, smooth surfaces and excellent morphology on stainless steel cathode plates, realizing efficient and low-pollution electrolytic refining of crude antimony under the green tartaric acid system.

The invention provides a high-corrosion-resistance nickel-copper-tin alloy replacing electroplating solution, a surface treatment method of rolled copper foil and the rolled copper foil. The copper-tin alloy electroplating solution comprises the following components: main salt, a coordination agent and a brightening agent. The main salt comprises copper salt and tin salt. The coordination agent comprises potassium methanesulfonate, an auxiliary coordination agent, ethylenediamine tetraacetic acid disodium salt and tetrahydroxypropyl ethylenediamine; the auxiliary coordination agent comprises at least one of gluconate, glycine, tartrate and citrate. The brightening agent comprises a primary brightening agent, sodium allysulfonate and benzotriazole; the primary brightener comprises polyethylene glycol and / or gelatin. When the electroplating liquid is used, the whole electroplating process can be environment-friendly and cyanide-free, the problems that a traditional cyanide-free copper and tin plating liquid is unstable and the performance of a plating layer is poor are solved, and a low-cost and high-performance nickel replacing scheme is provided for products needing high corrosion resistance, such as electronic connectors and antennas.

Pharmaceutical compositions comprising tartrate salts of medopredane and methods for making the pharmaceutical compositions are provided. The pharmaceutical composition is useful in the treatment of diseases such as L-DOPA induced dyskinesia.

The present disclosure provides a Dactylorhiza extract, a preparation method and uses thereof, and a pharmaceutical composition comprising the Dactylorhiza extract, wherein the Dactylorhiza extract is prepared by the following steps: mixing Dactylorhiza pseudobulbus with alcohol in a weight ratio of 1:5 to 1:10 to obtain a first extraction solution; wherein the alcohol is selected from the group consisting of methanol, ethanol, propanol, butanol, or any combination thereof; filtering the first extraction solution to remove chlorophyll and impurities to obtain a second extraction solution; and subjecting the second extraction solution to reverse-phase high-performance liquid chromatography to obtain the Dactylorhiza extract; wherein the Dactylorhiza extract comprises compounds dactylorhin D, dactylorhin B, 1-(4-β-D-glucopyranosyloxybenzyl)-2-isobutyl tartrate, loroglossin, or any combination thereof. The present disclosure also provides a pharmaceutical composition comprising the Dactylorhiza extract. The Dactylorhiza extract of the present disclosure has uses for preparing anti-inflammatory drugs.

Solid forms of (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol- 5-yl phenyl-carbamate tartrate, including crystalline (3aR)-l, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a- hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate (posiphen D-tartrate Form A), crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl- carbamate tartrate dihydrate (posiphen D-tartrate Form B), crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate Form A having the peak of Pattern C (posiphen D-tartrate Form A+Pattem C), and amorphous (3aR)-1, 3a, 8- trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate, are disclosed. Pharmaceutical compositions comprising posiphen D-tartrate Form A, posiphen D- tartrate Form B, posiphen D-tartrate Form A having the peaks of Pattern C, and amorphous posiphen D-tartrate, and methods of treating various conditions by administering these solid forms, are also disclosed.

A process of cleaning a reactor includes providing an alcohol-containing material to the reactor; and providing a metathesis catalyst to the reactor. The reactor contains a high molecular weight polymer gel and an organoaluminum material. The alcohol-containing material is not an alkyl tartrate and may be selected from triisopropanolamine, 4-tert-butylcatechol, isopropanol, and phenol formaldehyde resins.

This invention discloses a pH-responsive MOF nanocomposite chromium-free tanning agent, its preparation method, and its application, belonging to the technical field of chromium-free tanning agents for leather. The method disclosed in this invention involves forming a ligand with a borate ester module through the dehydration condensation of 4-carboxyphenylboronic acid and tartaric acid, and then binding zirconium to the ligand via a solvothermal method to form a MOF tanning agent. Subsequently, zirconium tartrate is loaded onto the MOF, enabling controlled release of zirconium tartrate through a pH-responsive switch in the ligand. This improves the problem of uneven tanning caused by the rapid and strong binding of zirconium ions to collagen fibers, resulting in tanned leather with a shrinkage temperature exceeding 80 °C, thereby effectively improving the quality of zirconium-tanned leather products.

Disclosed are solid forms of (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl carbamate tartrate, including crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl carbamate tartrate (Fenicillin D-tartrate Form A), crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl carbamate tartrate (Fenicillin D-tartrate Form B), crystalline (3aR)-1, 3a, 8- The present invention relates to a (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3-b) indol-5-ylphenylcarbamate tartrate dihydrate (Fenidin D-tartrate Form B), crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-ylphenylcarbamate tartrate Form A (Fenidin D-tartrate Form A + Pattern C) having peaks of pattern C, and amorphous (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8, 8-hexahydropyrrolo (2, 3-b) indol-5-ylphenylcarbamate tartrate Form B) having peaks of pattern C, the invention relates to 1, 3, 5, 7, 8a-hexahydropyrrolo (2, 3-b) indole-5-yl phenyl carbamate tartrate and a preparation method thereof. Also disclosed are pharmaceutical compositions comprising a Fetinil D-tartrate Form A, a Fetinil D-tartrate Form B, a Fetinil D-tartrate Form A having a peak of pattern C, and an amorphous Fetinil D-tartrate, and methods of treating various conditions by administering these solid forms.

The present invention relates to (R)-4-[5-(4-chlorophenyl)-1-[2-(trifluoromethyl)-phenyl]pyrrol-2-yl]-N-[2-(dimethylamino)-ethyl]benzamide (+)-L-tartrate salt, methods for its preparation, pharmaceutical compositions containing it and its use in treating diseases such as cancer.

Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and / or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

The invention relates to compounds of formula (I) or (II) (I), (II), A- being a counter-anion selected from the following ions: chloride, bromide, iodide, acetate, methanesulfonate, benzenesulfonate, camphosulfonate, tartrate, dibenzoate, ascorbate, fumarate, citrate, phosphate, salicylate, oxalate, bromohydrate, tosylate, and X being a 3-carbon alkyl group. The invention also relates to these compounds for their use as a medicinal product, particularly in the treatment of neuropsychiatric disorders. Figure to be published with the abstract: Figure 1

The application provides a preparation method of milorin benzenesulfonate, and the preparation method comprises the following steps: performing a hydrolysis reaction on a compound 6 to obtain a compound 7; and performing a reaction on the compound 7 and benzenesulfonic acid to obtain a compound 8, i.e. milorin benzenesulfonate. The preparation method does not produce carbon-carbon double bond isomer impurities, does not use the toxic substance NaCN in the preparation method, raw materials are easy to obtain, the method is simple, the synthesis cost is low, and the product has a high yield.

The invention relates to taste-masking enteric-coated acetylisovaleryltylosin tartrate tablets, which are characterized by comprising 1000 tablets, the acetylisovaleryltylosin tartrate tablet comprises the following main components by weight: 25 to 75 g of acetylisovaleryltylosin tartrate, 75 to 225 g of hydroxypropyl-beta-cyclodextrin, 7 to 9 g of a pork liver flavoring agent, 18 to 22 g of a microcrystalline cellulose-silicification compound, 6 to 20 g of origanum oil nano-emulsion, 13 to 14 g of Eudragit L100-55, 5 to 6 g of nano-zinc oxide, 2 to 3 g of polyethylene glycol, 1 to 2 g of magnesium stearate and 0 to 45 g of lactose. The acetylisovaleryltylosin tartrate tablet can effectively improve the palatability of drugs, improve the bioavailability and stability, ensure the mixing uniformity of raw materials, and better manage the drug resistance problem, thereby improving the application effect of acetylisovaleryltylosin tartrate in animal husbandry.